Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines

REFERENCES

• Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Burris H. A., 3rd, Moore M. J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413
   PubMed Web of Science ®Google Scholar
• Funk C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871–1875
   PubMed Web of Science ®Google Scholar
• Myers L. K., Kang A. H., Postlethwaite A. E., et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 2000; 43: 2687–2693
   PubMed Web of Science ®Google Scholar
• Ding X. Z., Hennig R., Adrian T. E., et al. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer 2003; 2: 10
   PubMedGoogle Scholar
• Yip-Schneider M. T., Barnard D. S., Billings S. D., et al. Cyxlooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 139–146
   PubMed Web of Science ®Google Scholar
• Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 1998; 90: 1529–1536
   PubMed Web of Science ®Google Scholar
• Sheng H., Shao J., Washington M. K., et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 2001; 276: 18075–18081
   PubMed Web of Science ®Google Scholar
• Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000; 19: 19–27
   PubMed Web of Science ®Google Scholar
• Aggarwal S., Tanej N., Lin L., et al. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome c independent of COX-2 expression. Neoplasia 2000; 2: 346–356
   PubMed Web of Science ®Google Scholar
• Gupt R. A., Dubois R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001; 1: 11–21
   PubMed Web of Science ®Google Scholar
• Molin M. A., Sitja-Arnau M., Lemoine M. G., et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by non-steroidal anti-inflammatory drugs. Cancer Res. 1999; 59: 4356–4362
   PubMed Web of Science ®Google Scholar
• Perugini R. A., McDade T. P., Vittimberg F. J., Jr., et al. Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J. Gastrointest. Surg. 2000; 4: 24–32
   PubMed Web of Science ®Google Scholar
• Kokawa A., Kondo H., Gotoda T., et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001; 91: 333–338
   PubMed Web of Science ®Google Scholar
• El-Rayes B. F., Ali S., Sarkar F. H., et al. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 2004; 3: 1421–1426
   PubMed Web of Science ®Google Scholar
• Solomon S. D., McMurray J. J., Pfeffer M. A., et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005; 352: 1071–1080
   Google Scholar
• Bresalier R. S., Sandler R. S., Quan H., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005; 352: 1092–1102
   PubMed Web of Science ®Google Scholar
• Nussmeier N. A., Whelton A. A., Brown M. T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 2005; 352: 1081–1091
   PubMed Web of Science ®Google Scholar
• Takada Y., Bhardwaj A., Potdar P., et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247–9258
   PubMed Web of Science ®Google Scholar
• Cheng A. L., Hsu C. H., Lin J. K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21: 2895–2900
   PubMed Web of Science ®Google Scholar
• Sharma R. A., Euden S. A., Platton S. L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004; 10: 6847–6854
   PubMed Web of Science ®Google Scholar
• Garcea G., Jones D. J., Sing R., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 2004; 90: 1011–1015
   PubMed Web of Science ®Google Scholar
• Lev-Ari S., Strier L., Kazanov D., Elkayam O., Lichtenberg D., Caspi D., Arber N. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 2006; 45: 171–177
   PubMed Web of Science ®Google Scholar
• Lev-Ari S., Strier L., Kazanov D., Madar-Shapiro L., Dvory-Sobol H., et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 2005; 11: 6738–66744
   PubMed Web of Science ®Google Scholar
• Goel A., Boland C. R., Chauhan D. P. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001; 172: 111–118
   PubMed Web of Science ®Google Scholar
• Zhang F., Altorki N. K., Mestre J. R., et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445–451
   PubMed Web of Science ®Google Scholar
• Aggarwal B. B., Kumar A., Bharti A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23: 363–398
   PubMed Web of Science ®Google Scholar
• Suh H. W., Kang S., Kwon K. S. Curcumin attenuates glutamate-induced HT22 cell death by suppressing MAP kinase signaling. Mol. Cell Biochem. 2006, November 25 [Epub]
   PubMed Web of Science ®Google Scholar
• Lee K. W., Kim J. H., Lee H. J., Surh Y. J. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid. Redox Signal 2005; 7: 1612–1620
   PubMed Web of Science ®Google Scholar
• Dannenberg A. J., Lippman S. M., Mann J. R., et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. 2005; 23: 254–266
   PubMed Web of Science ®Google Scholar
• Starr A., Vexler A., Ashkenazi-Voghera M., et al. Establishment and characterization of a pancreatic carcinoma cell line derived from a human metastatic pleural effusion. Oncology 2005; 69: 239–245
   PubMed Web of Science ®Google Scholar
• Starr A., Greif J., Vexler A., Ashkenazy-Voghera M., Gladesh V., et al. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int. J. Cancer 2006; 119: 269–74
   PubMed Web of Science ®Google Scholar
• Arber N., Doki Y., Han E. K., et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997; 57: 1569–1574
   PubMed Web of Science ®Google Scholar
• Jaiswal A. S., Marlow B. P., Gupta N., et al. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002; 21: 8414–8427
   PubMed Web of Science ®Google Scholar
• Khafif A., Schantz S. P., Chou T. C., et al. Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 1998; 19: 419–424
   PubMed Web of Science ®Google Scholar
• Lev-Ari S., Starr A., Vexler A., Karaush V., Loew V., et al. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res. 2006; 26: 4423–4430
   PubMed Web of Science ®Google Scholar
• Chendil D., Ranga R. S., Meigooni D., Sathishkumar S., Ahmed M. M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23: 1599–1607
   PubMed Web of Science ®Google Scholar
• Bharti A. C., Donato N., Singh S., Aggarwal B. B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053–1062
   PubMed Web of Science ®Google Scholar
• Harbottle A., Daly A. K., Atherton K., Campbell F. C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int. J. Cancer 2001; 92: 777–783
   PubMed Web of Science ®Google Scholar
• http://www.cancer.gov/
   Google Scholar
• Erkan M., Kleeff J., Esposito I., et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 24: 4421–4432
   PubMed Web of Science ®Google Scholar
• Hwang J. T., Kim Y. M., Surh Y. J., Baik H. W., Lee S. K., Ha J., Park O. J. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res. Oct 15, 2006; 66(20)10057–10063
   PubMed Web of Science ®Google Scholar
• Hwang D., Jang B. C., Yu G., Boudreau M. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide mediation through both mitogen-activated protein kinase and NF-B signaling pathways in macrophages. Biochem. Pharmacol. 1997; 54: 87–96
   PubMed Web of Science ®Google Scholar
• Pouliot M., Baillargeon J., Lee J. C., Cleland L. G., James M. J. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. J. Immunol. 1997; 158: 4930–4937
   PubMed Web of Science ®Google Scholar
• Krysan K., Reckamp K. L., Dalwadi H., Sharma S., Rozengurt E., Dohadwala M., Dubinett S. M. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005; 65: 6275–81
   PubMed Web of Science ®Google Scholar
• Gao J., Niwa K., Takemura M., Sun W., Onogi K., et al. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int. J. Oncol. 2005; 26: 737–744
   PubMed Web of Science ®Google Scholar
• Fujisawa S., Atsumi T., Ishihara M., Kadoma Y. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res. 2004; 24: 563–569
   PubMed Web of Science ®Google Scholar
• Joe B., Lokesh B. R. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim. Biophys. Acta 1994; 1224: 255–63
   PubMed Web of Science ®Google Scholar